Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Housaiyin Li(UPMC Hillman Cancer Center), Robert L. Ferris(University of Pittsburgh), Lazar Vujanović(UPMC Hillman Cancer Center), Gabriel Sica(Emory University), Kevin J. Contrera(Johns Hopkins University), Dan P. Zandberg(University of Pittsburgh Medical Center), Mark Kubik(UPMC Hillman Cancer Center), Brian R. Isett(UPMC Hillman Cancer Center), Tullia C. Bruno(University of Pittsburgh), Matthias Brand(UPMC Hillman Cancer Center), Umamaheswar Duvvuri(City University of New York), Curtis Tatsuoka(University of Maryland, Baltimore), Shaum Sridharan(University of Pittsburgh), Jing Hong Wang(UPMC Hillman Cancer Center), Simion I. Chiosea(University of Pittsburgh), Aditi Kulkarni(University of North Carolina at Chapel Hill), Anthony R. Cillo(University of Pittsburgh), Jie Chen(Second People’s Hospital of Yibin), Seungwon Kim(UPMC Hillman Cancer Center), Patricia M. Santos(UPMC Hillman Cancer Center), Marion Joy(UPMC Hillman Cancer Center), Fei Tu(Key Laboratory of Guangdong Province), Riyue Bao(UPMC Hillman Cancer Center), Dario A.A. Vignali(University of Pittsburgh)
Cited by 64
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899